Theralase's data point to enhanced cancer cell kill

Executive Summary

• Theralase Technologies Inc. announced in vitro data demonstrating that its light-activated Ruvidar, when combined with recombinant human interferon alpha-2b, results in significantly enhanced bladder cancer cell kill compared to Ruvidar alone.
• The combination therapy showed a 50 to 65 percent higher total cell kill in T24 human bladder cancer cells, with enhanced cytotoxic effects observed across increasing concentrations of interferon, suggesting a strong additive effect.
• These preclinical findings support the scientific rationale for an upcoming combinational clinical study targeting patients with Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS).

Key Details

• Study Type: In vitro preclinical research on T24 human bladder cancer cells.
• Treatment Protocol: Cells treated with two concentrations of light-activated Ruvidar (or left untreated), activated with green light, then exposed to increasing doses of rhIFNalpha2b.
• Efficacy Metrics:
  • Light-activated Ruvidar induced dose-dependent cytotoxicity.
  • rhIFNalpha2b induced dose-dependent cytotoxicity.
  • The combination of light-activated Ruvidar with rhIFNalpha2b resulted in 50 to 65 per cent higher total cell kill compared with no light-activated Ruvidar.
  • Enhanced cytotoxic effects were observed across increasing concentrations of rhIFNalpha2b, indicating a strong additive effect.
• Mechanism of Action:
  • Light-activated Ruvidar: Directly kills tumour cells, triggering immune recognition by releasing tumour-specific signals that activate innate and adaptive immune responses.
  • Interferon alpha-2b: Slows cancer cell growth, triggers cell death, and stimulates immune activity within the bladder.
  • Synergy: Ruvidar-induced tumour reduction and immune activation may increase the sensitivity of residual tumour cells to interferon activity.
• Clinical Application: The findings support the design of an upcoming combinational clinical study for patients diagnosed with BCG-unresponsive NMIBC CIS with or without resected papillary disease (plus or minus Ta/T1).
• Management Commentary:
  • Mark Roufaiel, PhD (Research Scientist): Noted that findings provide mechanistic support for the clinical study, aiming to create a microenvironment more responsive to interferon alpha-2b.
  • Arkady Mandel, MD, PhD, DSc (Chief Scientific Officer): Stated that the approach aligns with current thinking on combining drugs for higher efficacy, duration of response, and safety.
  • Roger DuMoulin-White, BSc, PEng, ProDir (President, CEO, and Chairman): Emphasized that preclinical research has successfully supported previous clinical program designs and expressed anticipation for upcoming clinical data.

Notable Quotes

• "These findings provide mechanistic support for our combinational clinical study. By inducing targeted tumour destruction and immune activation with light-activated Ruvidar, we hope to create a microenvironment more responsive to interferon alpha-2b. The enhanced total cell kill observed in vitro supports the potential of this complementary approach to improve outcomes for patients with BCG unresponsive NMIBC." — Mark Roufaiel, PhD
• "Our preclinical research demonstrates that light-activated Ruvidar combined with interferon may provide significant benefit to patients afflicted with high-risk BCG unresponsive NMIBC CIS, with or without papillary tumours. This combinational approach aligns with current thinking of combining world-class drugs to offer even higher efficacy, duration of response and safety for patients. I believe that the strong preclinical results demonstrated today will be confirmed clinically in the upcoming collaborative clinical study." — Arkady Mandel, MD, PhD, DSc
• "Our preclinical research has been used successfully to support design and development of our clinical programs. This has allowed our clinical programs to succeed, both in safety and efficacy, as they are firmly rooted in science. I look forward to reviewing the clinical data from the upcoming combinational clinical study." — Roger DuMoulin-White, BSc, PEng, ProDir